Vigilance warning over potential clotting risk in trials of JAK inhibitors for COVID-19

A group of clinicians has called for vigilance over the use of JAK inhibitors in patients with COVID-19 because of a potential increased risk of blood clots. Several randomised controlled trials have been set up to look at the use of JAK inhibitors in treating COVID-19 because of their dual anti-inflammatory and anti-viral effects. But ...

Already a member?

Login to keep reading.

© 2021 the limbic